Cohance Lifesciences Stock and Share Price Insights with New CEO Appointment

Cohance Lifesciences Stock Surges

Cohance Lifesciences share price today has skyrocketed by 20%, reaching ₹432.70 on the BSE. The catalyst for this significant increase is the recent announcement regarding the appointment of Umang Vohra as the new CEO and Executive Chairman, effective May 1, 2026.

Impact of Leadership Change

• Umang Vohra, known for transforming Cipla, is expected to lead Cohance towards becoming India’s top technology-driven CDMO.
• Trading volumes surged over threefold, with 14.71 million shares traded on the NSE and BSE.
• There are pending buy orders for approximately 650,000 shares, indicating strong investor confidence.

Market Performance Overview

With today’s gain, the stock price has rebounded 62% from its 52-week low of ₹267.85, which was recorded on March 9, 2026.

Cohance Lifesciences operates across three key segments: pharma CRDMO, specialty chemicals, and API++. Recently, it has made significant strides in the competitive ADCs market.

Rating Insights and Future Outlook

• India Ratings and Research expects the business profile to improve in the medium term.
• Despite current challenges, Cohance's pipeline offers long-term revenue visibility.
• Exports accounted for 87% of revenue in FY25, highlighting its strong presence in regulated markets.

Investors are keen on the navigating the evolving landscape of Cohance Lifesciences as it gears up for growth under new leadership.